---
document_datetime: 2024-12-16 10:54:49
document_pages: 50
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nimenrix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: nimenrix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 25.5360816
conversion_datetime: 2025-12-18 22:55:19.910314
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Nimenrix

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                     |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0136/G            | This was an application for a group of variations. B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol | 24/10/2024                          |                                             | SmPC                             | Section 6.3 of the SmPC is modified to reflect the addition of a temporary temperature excursion for the unopened vial: The unopened vial is stable for 72 hours when stored at temperatures from 0 째C to 2 째C or from 8 째C to 25 째C. At the end of this period, Nimenrix should be used or |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |             | discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursions only.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|--------------------------------------------------------------------------------------------------------------------------|
| II/0137   | Update of section 4.8 of the SmPC in order to add 'hypersensitivity' and 'Anaphylaxis' to the list of adverse drug reactions (ADRs) with frequency 'uncommon' and 'not known' respectively, following PRAC's recommendation for procedure EMEA/H/002226/PAM/LEG/058. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with | 05/09/2024 |     | SmPC and PL |                                                                                                                          |
| IB/0138/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                          | 20/08/2024 | n/a |             |                                                                                                                          |
| II/0135   | Update of section 5.1 of the SmPC in order to update immunogenicity response information based on results from Study C0921062 and following EMEA/H/C/002226/P46/057 procedure. Study                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/07/2024 |     | SmPC        | Please refer to Scientific Discussion 'Nimenrix EMEA/H/C/002226/II/0135'                                                 |

<div style=\"page-break-after: always\"></div>

|           | 3b, open-label, with a single- arm design study, to evaluate the safety and immunogenicity of a single dose of Nimenrix in infants at 3 months of age, followed by a booster dose at 12 months of age. In addition, the MAH took the opportunity to implement editorial changes in the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                       |            |     |              | C0921062 is a Phase   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------|-----------------------|
| II/0130/G | This was an application for a group of variations. B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test | 21/03/2024 | n/a |              |                       |
| IAIN/0134 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/02/2024 |     | Annex II and |                       |

<div style=\"page-break-after: always\"></div>

|                     | responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     | PL   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------------------------|
| IB/0132/G           | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                              | 06/02/2024 | n/a |      |                                   |
| IB/0133/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 24/01/2024 | n/a |      |                                   |
| IB/0131             | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                    | 07/12/2023 | n/a |      |                                   |
| PSUSA/10044 /202304 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                                                                                                                                                                                                                             | 30/11/2023 | n/a |      | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0127   | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 30/11/2023   | n/a   |                                        |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------------------------------|
| II/0129/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product | 09/11/2023   | n/a   | B.I.a.1.e - Change in the manufacturer |

<div style=\"page-break-after: always\"></div>

|           | starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                       |            |     |                        |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| II/0126/G | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the        | 13/07/2023 | n/a | change requires        |
| II/0125/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product A.7 - Administrative change - Deletion of manufacturing sites | 25/05/2023 | n/a |                        |
| II/0120/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation - Active substance - Other                                                                                                                                                | 30/03/2023 | n/a | B.I.z - Quality change |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| variation B.I.z - Quality change - Active substance - Other variation B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------|
| IB/0124   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 31/01/2023 | n/a |       |
| IB/0122   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 31/01/2023 | n/a | batch |
| IB/0121/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.c.1.z - Change in immediate packaging of the AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 31/01/2023 | n/a |       |

<div style=\"page-break-after: always\"></div>

|                     | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0123             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 12/12/2022 | n/a |                                   |
| PSUSA/10044 /202204 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 01/12/2022 | n/a | PRAC Recommendation - maintenance |
| IB/0118/G           | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the | 04/08/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products   |            |            |                   |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0117/G           | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                      | 09/06/2022 | n/a        |                   |                                                                                                                                            |
| IA/0116             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                     | 12/05/2022 | 23/02/2023 | Annex II and PL   |                                                                                                                                            |
| II/0115             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                 | 31/03/2022 | 23/02/2023 | SmPC and Annex II |                                                                                                                                            |
| PSUSA/10044 /202104 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                  | 16/12/2021 | 28/02/2022 |                   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10044/202104. |
| IB/0114             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                  | 24/11/2021 | n/a        |                   |                                                                                                                                            |
| IB/0113             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                               | 24/11/2021 | n/a        |                   |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|
| II/0112   | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18/11/2021 | n/a |                                  |
| II/0111/G | application for a group of variations. B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change process | 30/09/2021 | n/a | This was an in the manufacturing |
| II/0108/G | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 02/09/2021 | n/a |                                  |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                     |            |            |             |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0109/G           | This was an application for a group of variations. B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction                                                                                                                                                                   | 05/05/2021 | n/a        |             |                                                                                                                                            |
| IA/0107/G           | This was an application for a group of variations. B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test A.7 - Administrative change - Deletion of manufacturing sites B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test | 09/04/2021 | n/a        |             |                                                                                                                                            |
| PSUSA/10044 /202004 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                                                                                                                     | 10/12/2020 | 18/02/2021 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10044/202004. |
| II/0105             | To update section 5.1 Pharmacodynamic properties of the SmPC with information regarding the effectiveness of Nimenrix, to include real-world data                                                                                                                                                                                                                                                    | 11/02/2021 | 28/02/2022 | SmPC and PL | SmPC new text (Section 5.1) Impact of a single dose of Nimenrix.                                                                           |

<div style=\"page-break-after: always\"></div>

|           | from the Netherlands describing the impact of a single dose of Nimenrix on the prevention of meningococcal disease. In addition, a cross- reference to section 4.2 Posology and method of administration of the SmPC was included, to direct the physicians attention to the robust persistence and booster data in section 5.1 and information in section 4.4 Special warnings and precautions for use. In addition, the MAH took the opportunity to include minor editorial changes to the SmPC and to bring the Product information in line with the latest QRD update. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             | In 2018, the Netherlands added Nimenrix to the national immunisation programme as a single dose for toddlers at 14 months of age to replace the meningococcal C conjugate vaccine. A catch-up campaign with a single dose of Nimenrix for adolescents 14-18 years of age also initiated in 2018, and it became routine in 2020 leading to a toddler and adolescent national immunisation programme. Within two years, the incidence of meningococcal disease caused by groups C, W, and Y was significantly reduced by 100% (95% CI: 14, 100) in individuals 14-18 years of age, 85% (95% CI: 32, 97) in all vaccine eligible ages (direct effect), and 50% (95% CI: 28, 65) in non-vaccine eligible ages (indirect effect). The impact of Nimenrix was primarily driven by a reduction in group W disease. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0106   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21/12/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0104   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 03/11/2020 | 18/02/2021 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0103   | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 09/10/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0099/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 23/07/2020 | 18/02/2021 | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| manufacturing sites B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.e - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter effect on the overall quality B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.c.1.b - Change in immediate - Qualitative and/or quantitative sterile and non-frozen B.I.c.1.z - Change in immediate - Other variation B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.1.z - Change in the starting material/reagent/intermediate   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | - Change in the manufacturer of AS or of a material/reagent/intermediate for AS - Other                                                                                                                                                                                                                                      |            |            |                        | B.I.a.1.z starting variation   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| II/0098   | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol                                                     | 09/07/2020 | n/a        |                        |                                |
| IB/0100   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                  | 29/06/2020 | n/a        |                        |                                |
| IA/0101   | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                                                        | 18/06/2020 | n/a        |                        |                                |
| II/0096   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                            | 30/01/2020 | 18/02/2021 | SmPC and PL            |                                |
| II/0095/G | This was an application for a group of variations. Grouping of variations to support the introduction of Pfizer Ireland Pharmaceuticals (Grange Castle Business Park, Clondalkin, Dublin 22, Ireland) as an alternative manufacturing and quality control testing site for the MenAAH-TT, MenCAH-TT, MenW-TT and Substances. | 16/01/2020 | 18/02/2021 | SmPC, Labelling and PL | MenY-TT Drug                   |

<div style=\"page-break-after: always\"></div>

| Grouping of variations to support the registration of a new vial/vial presentation (EU/1/12/767/008) to replace the existing vial/ampoule presentations. As a consequence of the introduction of the new vial/vial presentation, the vial/ampoule presentations (EU/1/12/767/005-006-007) are being withdrawn. Hence, the 0.9% NaCl Diluent in ampoules (primary packaging container) as currently manufactured at Delpharm Belgium is withdrawn, as well as the associated secondary packaging site (CRNA Belgium) used for the related pack-size. This grouping of variations supports the introduction of Pfizer Puurs Belgium as a manufacturing and quality control site for the 0.9% NaCl Diluent in vials used for MenACWY-TT Drug Product reconstitution for the new vial/vial presentation. In addition, release specifications have been updated to align with compendial requirements. Product Information (PI) revisions in line with the above changes affect Annex I, IIIA and IIIB, as well as Annex A (All Authorised Presentations). In addition, the MAH took the opportunity to align SmPC section 4.4 and Annex II with the latest QRD requirement. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.f - Replacement or addition of a   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the   |            |            |          |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|
| II/0094/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.e - Change in the manufacturer of AS or of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/01/2020 | 18/02/2021 | Annex II |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate   | Replacement   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|

<div style=\"page-break-after: always\"></div>

|                     | control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure   |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0097/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                 | 17/12/2019 | n/a |                                   |
| PSUSA/10044 /201904 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 31/10/2019 | n/a | PRAC Recommendation - maintenance |
| II/0092/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 12/09/2019 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier   |            |            |             |                                                                                                                                                                                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0093   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 06/09/2019 | n/a        |             |                                                                                                                                                                                     |
| IB/0090/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                    | 02/07/2019 | n/a        |             |                                                                                                                                                                                     |
| IA/0089   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                     | 06/05/2019 | n/a        |             |                                                                                                                                                                                     |
| II/0084   | Update of section 4.2 of the SmPC in order to update the posology information in infants, based on data from study MenACWY-TT-087 (a phase IIIb, controlled, randomised, open study aimed to                                                                                                                                                                                                                                                                                                                                                            | 28/02/2019 | 04/10/2019 | SmPC and PL | The Nimenrix posology instructions were given for infants (i) at 6-12 weeks of age and (ii) at >1yr old, thus leaving a gap in advice for those between 12 weeks and 1 year of age. |

<div style=\"page-break-after: always\"></div>

|           | demonstrate the immunogenicity and safety of Nimenrix in healthy infants) and MenACWY-TT-083 (an open-label, randomised and active controlled study). As a consequence, sections 4.4, 4.8 and 5.1 were updated. The MAH took the opportunity to include editorial changes in sections 4.4 and 4.8 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                         |            |     | A post-hoc extrapolation exercise based on clinical studies MenACWY-TT-087 and MenACWY-TT-083 was carried out by the MAH. The data presented support (i) a 2+1 posology for infants aged 6 weeks to 6 months and (ii) a 1+1 posology for infants from 6 to 12 months of age. The posology instructions in SmPC section 4.2 have been re-written in line with the accepted posology and presented under new headings to emphasise 'Primary immunisation' vs 'Booster doses'. Within each heading, the instructions have been stratified by age group. Sections 4.4, 4.8 and 5.1 have also been updated with the appropriate information relating to the updated posology.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0086/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a | 24/01/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | biol/immunol method B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.f.1.e - Stability of FP - Change to an approved stability protocol   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0083 | Update of section 4.4 of the SmPC in order to include a safety warning regarding the risk for invasive disease caused by Meningococcal polysaccharide serogroups A, C, W-135 and Y in persons with familial complement deficiencies and persons receiving treatments that inhibit terminal complement activation. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                     | 13/12/2018 | 04/10/2019 | SmPC | Based on the review of the literature reports well as the cases from the MAH's safety database the Nimenrix SmPC has been updated to reflect that persons with familial complement deficiencies (for example, C5 or C3 deficiencies) and persons receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis groups A, C, W-135 and Y, even if they develop antibodies following vaccination with Nimenrix. |
| IA/0088 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                            | 07/12/2018 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| PSUSA/10044 /201804   | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                                                                                                                                                                                          | 31/10/2018   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IA/0087/G             | This was an application for a group of variations. B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 28/09/2018   | n/a        |                        |                                     |
| IB/0085               | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                      | 17/09/2018   | n/a        |                        |                                     |
| II/0082               | B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol                                                                                                                                                                                                                                                                       | 13/09/2018   | 04/10/2019 | SmPC                   |                                     |
| T/0080                | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/07/2018   | 30/07/2018 | SmPC, Labelling and PL |                                     |
| IA/0079/G             | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/07/2018   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

|             | A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                            |            |            |             |                                                                                                                                                                                                                                                                                                                                                                  |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0078     | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                         | 12/07/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0077     | B.I.c.1.z - Change in immediate packaging of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                  | 11/04/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0076/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                          | 26/03/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                  |
| II/0074     | Update of sections 4.5 of the SmPC to include new information regarding co-administration of Nimenrix with Boostrix and Cervarix in individuals from the age of 9 to 25 years, based on data from Studies MenACWY-TT-098 (116705- Phase 3 study to demonstrate the non-inferiority of Nimenrix co- administered with Boostrix compared to Nimenrix administered alone) and MenACWY-TT-054 (113823- phase 3 study to demonstrate the non-inferiority of | 15/03/2018 | 30/07/2018 | SmPC and PL | The MAH has updated the Product Information to include new information regarding co-administration of Nimenrix with a combined diphtheria (reduced antigen content), tetanus and acellular pertussis vaccine and the human papillomavirus vaccine [Types 16, 18] in individuals from the age of 9 to 25 years. The SmPC section 4.5 has been updated as follows: |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | Nimenrix co-administered with Cervarix compared to Nimenrix alone). The Package Leaflet is updated accordingly. The MAH took also the opportunity to make editorial revision to section 4.8 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | [] In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus bivalent [Type 16 and 18] vaccine, recombinant (HPV2). [] One month after co-administration with a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Tdap) in subjects aged 9 to 25 years, lower GMCs were observed to each pertussis antigen (pertussis toxoid [PT], filamentous haemagglutinin [FHA] and pertactin [PRN]). More than 98% of subjects had anti- PT, FHA or PRN concentrations above the assay cut-off thresholds. The clinical relevance of these observations is unknown. There was no impact of co-administration on immune responses to Nimenrix or the tetanus or diphtheria antigens included in Tdap. The PL (section 2) has been updated accordingly. Other medicines and Nimenrix [] In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus bivalent [Type 16   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0075 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                                                                                                                                                                                                       | 12/03/2018 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |      |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| II/0073             | C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                      | 22/02/2018 | 30/07/2018 | SmPC |                                   |
| II/0069             | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                                                                                                         | 25/01/2018 | n/a        |      |                                   |
| PSUSA/10044 /201704 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 26/10/2017 | n/a        |      | PRAC Recommendation - maintenance |
| IA/0072/G           | This was an application for a group of variations. B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change | 19/10/2017 | n/a        |      |                                   |

<div style=\"page-break-after: always\"></div>

|           | of the Ph. Eur. or national pharmacopoeia of a Member State B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State   |            |            |           | to comply with an update   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|----------------------------|
| IB/0070/G | This was an application for a group of variations. B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                               | 19/10/2017 | n/a        |           |                            |
| IB/0067   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                              | 07/09/2017 | n/a        |           |                            |
| N/0068    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                          | 17/08/2017 | 30/07/2018 | Labelling |                            |

<div style=\"page-break-after: always\"></div>

| IB/0065             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                             | 28/06/2017   | n/a        |             |                                                                                                                                                                                                                                                                        |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10044 /201610 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                         | 05/05/2017   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| IA/0064             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                             | 26/04/2017   | n/a        |             |                                                                                                                                                                                                                                                                        |
| R/0059              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                  | 15/12/2016   | 16/02/2017 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Nimenrix in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| II/0062             | B.I.d.1.a.3 - Stability of AS - Change in the re-test period/storage period - Extension of storage period of a biological/immunological AS not in accordance with an approved stability protocol                                                                         | 09/02/2017   | n/a        |             |                                                                                                                                                                                                                                                                        |
| II/0049             | Extension of Indication to include a wider paediatric population starting from 6 weeks of age for Nimenrix; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet and the RMP (version 6.0) are updated in accordance. | 10/11/2016   | 12/12/2016 | SmPC and PL | Please refer to the published Assessment Report Nimenrix H-2226-II-49-AR.                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                     | Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10044 /201604 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                                                                                                                                                                                                                                                                                        | 27/10/2016 | n/a        |             | PRAC Recommendation - maintenance |
| IAIN/0061/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                            | 22/09/2016 | n/a        |             |                                   |
| II/0058             | Update of section 4.5 of the SmPC in order to add new co-administration compatibility information with Prevenar. Section 5.1 is proposed to be updated following results of a new post hoc analyses conducted to exclude 5 additional subjects from the ATP cohort. In addition, the Marketing authorisation holder (MAH) took the opportunity to align the pharmaceutical form of Nimenrix in Section 3 with its product release specification following a complaint. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 15/09/2016 | 12/12/2016 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|         | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0060 | B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                          | 14/09/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0053 | Update of sections 4.2, 4.8 and 5.1 of the SmPC to reflect new booster and persistence data with a follow-up of up to 5 years after vaccination with MenACWY-TT. In addition, the MAH took the opportunity to make minor editorial changes in the SmPC, Labelling and Package Leaflet. An updated RMP version 7.1 was agreed during the procedure. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/07/2016 | 22/08/2016 | SmPC, Labelling and PL | Nimenrix may be given as a booster dose in individuals who have previously received primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines. In clinical trials, the use of Nimenrix as a booster following primary vaccination with Nimenrix or other meningococcal vaccines (quadrivalent meningococcal A, C, W, and Y-DT conjugate vaccine or monovalent MenC conjugate vaccines) was evaluated. Nimenrix booster vaccination after priming in toddlers, children, adolescents and adults: For subjects primed with Nimenrix aged 1 year and above and boosted with Nimenrix 4 or 5 years later, more than 99.0% of all subjects achieved post-booster SBA titres 1:8 for both assays (studies MenACWY-TT-062, 048, 059, 088). One month after the booster vaccination, the GMTs elicited were significantly higher than those elicited by age matched na챦ve control groups, indicating that Nimenrix induces immune memory to groups A, C, W-135, and Y. The observed MenC booster response with Nimenrix was similar to that observed in subjects primed and boosted with a monovalent MenC-CRM conjugate vaccine. One year after Nimenrix booster, SBA titres 1:8 persisted in at least 95.5% of subjects (study MenACWY-TT-048, 12 to 23 months of age at primary vaccination). When Nimenrix was used as a booster following primary vaccination with a MenACWY-DT conjugate vaccine or a |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                                  | monovalent MenC conjugate vaccine (study MenACWY-TT- 059, 10 to 25 years of age at primary vaccination and study MenACWY-TT-088, 2 to 10 years of age at primary vaccination), the titres increased by 48-340 fold for all groups and 100% of the subjects reached SBA titres 1:8. The local and general adverse reaction profile of a booster dose of Nimenrix after primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines, was similar to the local and general adverse reaction profile observed after primary vaccination with Nimenrix, except gastrointestinal symptoms (including diarrhoea, vomiting, and nausea) which were very common.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0045 | Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC in order to amend the information related to the vaccination phase of study MenACWY-TT-104 which includes immunogenicity results for the meningococcal vaccine antigens, and reactogenicity and safety up to one month after vaccination with one or two MenACWY-TT doses in toddlers. This change amends the condition related to study MenACWY-TT-104. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet. In addition the MAH is updating Annex II and IIIA in accordance with the QRD template (v.9.1). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of | 23/06/2016 | 29/07/2016 | SmPC, Annex II, Labelling and PL | Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC in order to amend the information related to the vaccination phase of study MenACWY-TT-104 which includes immunogenicity results for the meningococcal vaccine antigens, and reactogenicity and safety up to one month after vaccination with one or two MenACWY-TT doses in toddlers. This variation amends the condition related to study MenACWY-TT-104.                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           | by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| IB/0056/G | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a material/reagent/intermediate for AS - New | 24/06/2016 | n/a | starting    |
| IB/0055/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 31/05/2016 | n/a | B.I.a.2.a - |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   |            |            |                 |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10044 /201510 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/05/2016 | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0054             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 21/04/2016 | n/a        |                 |                                   |
| IAIN/0052           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 15/01/2016 | 29/07/2016 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0051           | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                              | 12/01/2016   | n/a        |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IB/0048/G           | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 17/12/2015   | n/a        |                        |                                   |
| T/0047              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 13/11/2015   | 16/12/2015 | SmPC, Labelling and PL |                                   |
| IA/0046             | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                               | 12/11/2015   | n/a        |                        |                                   |
| PSUSA/10044 /201504 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                                                                                                                                                                                                             | 06/11/2015   | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0044/G           | This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or                                                                                                                                                                                                                                                                                                                                                                                            | 18/09/2015   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|         | variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                             |            |     |           |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| WS/0748 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                         | 30/07/2015 | n/a |           |
|         | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the | 15/07/2015 | n/a | IB/0043/G |

<div style=\"page-break-after: always\"></div>

|                     | obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10044 /201410 | Periodic Safety Update EU Single assessment - meningococcal group a, c, w135, y conjugate vaccine (conjugated to tetanus toxoid carrier protein)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 07/05/2015 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0040             | Update of section 5.1 of the SmPC based on the results of a re-analysis that was performed excluding immunogenicity data from subjects impacted by GCP deviations for studies MenACWY-TT-036, MenACWY- TT-043 and MenACWY-TT-038, and which included antibody persistence Year 3- and Year 4- results from study MenACWY-TT-043, and Year 4- results for study MenACWY-TT-032. Further, the pooling of clinical safety data in section 4.8 of the SmPC has been updated, and section 4.2 of the SmPC has been updated with removal of the sentence on the need for a booster dose for increased clarity. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/03/2015 | 28/07/2015 | SmPC | The information in section 5.1 of the SmPC for 3 of the original Nimenrix studies has been updated as a consequence of the reanalysis of data following issues identified with GCP. The MAH has excluded data from subjects who had not been properly consented, or where serological data was missing. This includes 119 subjects from MenACWY-TT-036 (out of a total of 1025 subjects), 106 subjects from MenACWY-TT-038 (out of a total of 1501 subjects), and 9 subjects from MenACWY-TT-043 (out of a total of 689 subjects). The reason for the majority of exclusions from MenACWY-TT-036 and MenACWY-TT-038 was consent issues, rather than missing serological data. Furthermore, data from Years 3 and 4 in study MenACWY- TT-036 show persistent immunogenicity in adolescents. Persistence results from study MenACWY-TT-032 (Years 4 and 5 in toddlers) have also been updated to try to minimise the potential of selection bias, since subjects with rSBA MenC titres <8 before Year 4 were offered revaccination and excluded from later time points. The MAH |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                |            |            |          | has therefore updated the Year 4 immunogenicity data to reflect the cohort for whom Year 5 data are presented. It is agreed that this presentation of the immunogenicity data is more meaningful, and more accurately describes the persistence of response through Years 4 and 5. The MAH has also presented updated pooled safety information including data from two additional studies. An update without data from excluded sites following issues identified with GCP has also been presented. These updates do not significantly affect the reporting rates of solicited or unsolicited symptoms in either age-group. The variation does not have any impact on the overall benefit risk balance of Nimenrix, which remains positive.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0038 | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 26/03/2015 | 28/07/2015 | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0036 | B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP                                 | 26/03/2015 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0037 | To widen the approved specification limit of the description test performed during quality control release testing and stability testing of Nimenrix conjugate bulks.                                                                                                                          | 26/02/2015 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP                                     |            |     |           |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| WS/0663 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                               | 26/02/2015 | n/a | of the AS |
| II/0033 | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 18/12/2014 | n/a |           |
| IG/0498 | B.II.e.3.c - Change in test procedure for the immediate packaging of the finished product - Deletion of a test procedure if an alternative test procedure is already authorised                                                                                                                    | 21/11/2014 | n/a |           |
| WS/0600 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                      | 20/11/2014 | n/a |           |

<div style=\"page-break-after: always\"></div>

|           | Change in test procedure for the finished product B.II.d.2.z - Change in test procedure for the finished product - Other variation                                                                                                                                                                                               |            |            |                        |                                   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| WS/0615   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. minor change in the manufacturing process of the active substance B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 20/11/2014 | n/a        |                        |                                   |
| PSUV/0027 | Periodic Safety Update                                                                                                                                                                                                                                                                                                           | 06/11/2014 | n/a        |                        | PRAC Recommendation - maintenance |
| IG/0468   | B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                            | 20/08/2014 | n/a        |                        |                                   |
| IB/0028   | B.II.f.1.a.3 - Stability of FP - Reduction of the shelf life of the finished product - After dilution or reconstitution                                                                                                                                                                                                          | 20/08/2014 | 28/07/2015 | SmPC, Labelling and PL |                                   |
| IB/0029/G | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the                                                                                                                                                                                                                              | 12/08/2014 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing   |            |            |             |                                                                                                                                   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------|
| IB/0025   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/08/2014 | n/a        |             |                                                                                                                                   |
| PSUV/0020 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/05/2014 | 18/07/2014 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0020. |
| IG/0446   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 24/06/2014 | n/a        |             |                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|         | PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                   |                                                                    |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|--------------------------------------------------------------------|
| IB/0024 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/06/2014 | n/a        |                   |                                                                    |
| WS/0493 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                          | 25/04/2014 | n/a        |                   |                                                                    |
| IA/0022 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 18/04/2014 | n/a        |                   |                                                                    |
| II/0009 | Update of SmPC section 5.1 with long term data (up to 4 years after primary vaccination) on antibody persistence and booster response. The statements of persistence of serum bactericidal antibody titres in SmPC section 4.4 has been updated accordingly. In addition, editorial changes have been made in SmPC sections 4.2 and 5.1 and the Annex II has been updated in line with latest QRD template version. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 20/02/2014 | 23/04/2014 | SmPC and Annex II | Please refer to the assessment report: Nimenrix-H-C-2226- II-09-AR |
| II/0016 | Submission of results of a 5 year follow-up study of the pivotal phase III study MenACWY-TT-039. The                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/01/2014 | n/a        |                   | Please refer to the assessment report: Nimenrix-H-C-2226-          |

<div style=\"page-break-after: always\"></div>

|             | study report was submitted in line with requirements of Article 46 of Regulation (EC) No 1901/2006. The requested variation proposed no amendments to the PI. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |      | II-16-AR                                                                                                                                                                                                                            |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0019/G | This was an application for a group of variations. C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring A.z - Administrative change - Other variation                                 | 18/12/2013 | n/a        |      |                                                                                                                                                                                                                                     |
| IB/0018     | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                  | 17/12/2013 | n/a        |      |                                                                                                                                                                                                                                     |
| IB/0017     | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                  | 02/12/2013 | n/a        |      |                                                                                                                                                                                                                                     |
| IA/0015     | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                        | 25/10/2013 | n/a        |      |                                                                                                                                                                                                                                     |
| II/0014     | Update of SmPC sections 5.1 and 4.8 with immunogenicity and safety data in individuals above 55 years of age, based on results of a phase IIIb, open label, randomised, controlled study. In SmPC                                                                                                             | 24/10/2013 | 23/04/2014 | SmPC | The MAH submitted results of a study, where single dose of Nimenrix was administered to 194 Lebanese adults 56 years of age and older (including 133 aged 56-65 years and 61 aged > 65 years). The percentage of subjects with rSBA |

<div style=\"page-break-after: always\"></div>

|         | section 4.2 the statement on absence of data in elderly population is being removed accordingly. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                           |            |     | titres (measured at MAH's laboratories)  128 before vaccination ranged from 45% (MenC) to 62% (MenY). Overall, at one month post-vaccination the percentage of vaccinees with rSBA titres  128 ranged from 93% (MenC) to 97% (MenY). In the subgroup aged > 65 years the percentage of vaccinees with rSBA titres  128 at one month post-vaccination ranged from 90% (MenA) to 97% (MenY). All adverse reactions reported in this study were already observed in younger age groups.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0381 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.b - Change in the manufacturing process of the finished product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product                                           | 24/10/2013 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| WS/0383 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes on the manufacturing process of the active substance. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol | 27/06/2013 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IG/0306   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                             | 12/06/2013   | n/a        |          |    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|----|
| IG/0304   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                                      | 17/05/2013   | 23/04/2014 | Annex II |    |
| IG/0297   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                             | 19/04/2013   | n/a        |          |    |
| II/0005   | Change in the manufacturing process of the finished product. B.II.b.3.b - Change in the manufacturing process of the finished product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product                     | 21/03/2013   | n/a        |          |    |
| IA/0007   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                               | 04/02/2013   | n/a        |          |    |
| IG/0265/G | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the | 28/01/2013   | n/a        |          | DD |

<div style=\"page-break-after: always\"></div>

|             | - Changes to an existing pharmacovigilance as described in the DDPS - Other change(s) the DDPS that does not impact on the operation of pharmacovigilance system                                                                                                                                                 |            |     | C.I.9.h system to the         |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------|
| WS/0340     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change of specifications of reagent. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting - Other variation                         | 17/01/2013 | n/a | material/intermediate/reagent |
| IB/0003/G   | This was an application for a group of variations. B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation | 05/10/2012 | n/a |                               |
| IAIN/0001   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                               | 17/07/2012 | n/a |                               |
| IAIN/0002/G | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the                                                                                                                                                            | 12/07/2012 | n/a |                               |

<div style=\"page-break-after: always\"></div>

| back-up procedure of the QPPV   |
|---------------------------------|